
    
      This is a randomized, placebo-controlled, 4-period study. Eligible patients will undergo a
      single-blind phase in Period 1, followed by 3 periods during which they will receive low-dose
      MK-8351, high-dose MK-8351, or matching placebo as a single dose in a random sequence
      crossover study design.
    
  